ISSN: 2641-9459
Authors: Digvijay K*, da Luz LG, Virzi GM, Bhargava V, Taramsari MM and Ronco C
Signs and symptoms of chronic kidney disease (CKD) are usually not present during early stages of disease. If diagnosed early, the progression of CKD could be slowed down. Finding an early diagnostic or predictive marker is of great benefit for both nephrologists as well as patients. Recent development in metabolomics has shown a potential progress in finding a novel biomarker to predict disease progression. In recent years, tryptophan (TRP) metabolites have shown a possible role in CKD pathogenesis and progression of disease. There are accumulations of toxic TRP metabolites in CKD. This review presents possible role of TRP metabolites in CKD. However, for defining their role as a predictive biomarker more and large cohort studies are required.
Keywords: Chronic Kidney Disease; Tryptophan; Indoleamine 2,3-dioxygenase; Kynurenic Acid; Quinolinic Acid; Hemodialysis; Peritoneal Dialysis; Cardiovascular Disease; Chronic Kidney Disease; End Stage Renal Disease
